
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc has demonstrated a promising capability in its gene editing approach, achieving sustained FVIII levels of 80% over a 19-month period in a non-human primate study, indicating potential efficacy for its treatment candidates. The company's strategic focus on in vivo gene editing for its wholly-owned pipeline, combined with technology out-licensing for ex vivo cell therapy, positions it to maximize its proprietary metagenomics-derived genome editing toolbox. With product candidates targeting critical disorders, such as Hemophilia A and cardiovascular diseases, Metagenomi is well-positioned to address significant unmet medical needs, underscoring a favorable outlook for its stock.
Bears say
Metagenomi Inc reported a significant net loss of $19.9 million, or $0.54 per share, for the second quarter of 2025, highlighting ongoing financial challenges amid their research and development efforts. The company faces multiple risks that may adversely affect its future prospects, including potential delays in clinical assessments and the need to generate favorable clinical data for key programs, particularly in Hemophilia A and TTR. Additionally, there are concerns about long-term dilution risk, which could negatively impact shareholder value as the company attempts to fund its operations and growth initiatives.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares